Form 8-K - Current report:
SEC Accession No. 0001213900-24-059104
Filing Date
2024-07-03
Accepted
2024-07-03 17:00:10
Documents
13
Period of Report
2024-06-28
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0208909-8k_virpax.htm   iXBRL 8-K 27415
  Complete submission text file 0001213900-24-059104.txt   203087

Data Files

Seq Description Document Type Size
2 XBRL SCHEMA FILE vrpx-20240628.xsd EX-101.SCH 3027
3 XBRL LABEL FILE vrpx-20240628_lab.xml EX-101.LAB 34240
4 XBRL PRESENTATION FILE vrpx-20240628_pre.xml EX-101.PRE 22367
15 EXTRACTED XBRL INSTANCE DOCUMENT ea0208909-8k_virpax_htm.xml XML 3804
Mailing Address 1055 WESTLAKES DRIVE, SUITE 300 BERWYN PA 19312
Business Address 1055 WESTLAKES DRIVE, SUITE 300 BERWYN PA 19312 610-727-4597
Virpax Pharmaceuticals, Inc. (Filer) CIK: 0001708331 (see all company filings)

EIN.: 821510982 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40064 | Film No.: 241100790
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)